Skip to main content

at its Source


At Galimedix, we are working to improve the lives of millions of patients worldwide by developing game-changing drugs to treat major neurodegenerative diseases where amyloid beta plays a role and where better treatments are urgently needed, including dry AMD, glaucoma and Alzheimer’s disease, our initial areas of focus.

Galimedix’s approach is to block a key step in the neurodegenerative process with a highly specific and well tolerated compound without impacting normal neuronal function

Treating Neurodegeneration of the Eye and Brain

We are currently developing two small molecules with a unique mechanism of action that allows us to tackle the root cause of and alter the course of disease. GAL-101, Galimedix’s lead clinical candidate is a Phase 2 treatment for dry age-related macular degeneration (dry AMD) and glaucoma. GAL-201 is in pre-clinical testing for Alzheimer’s disease.

Designed to be patient friendly

Our product candidates can be delivered via convenient administration routes – as eye drops or orally – easy for the patient and caregiver and less burdensome to the healthcare system. More importantly, they are designed to be well tolerated with fewer side effects than current treatment options.